Source MS Society:
The European Medicines Agency (EMA) has licensed cladribine (also known as Mavenclad) to treat people with highly active relapsing MS.
The National Institute for Health and Care Excellence (NICE) will now decide whether to make it available on the NHS in England and Wales. The Scottish Medicines Consortium (SMC) will decide for Scotland.
How does it work? Cladribine is currently used as an anti-cancer drug. In MS, the body’s own immune cells...